Detalhe da pesquisa
1.
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
Haemophilia;
28(6): 1033-1043, 2022 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35905294
2.
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
N Engl J Med;
379(9): 811-822, 2018 08 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30157389
3.
Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis.
J Hepatol;
69(2): 368-377, 2018 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29709678
4.
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression.
Eur Respir J;
43(5): 1430-8, 2014 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24177001
5.
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Res Pract Thromb Haemost;
8(1): 102306, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38282901
6.
Clinical pharmacology of emicizumab for the treatment of hemophilia A.
Expert Rev Clin Pharmacol;
16(9): 775-790, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37529848
7.
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment.
Cancer Discov;
13(11): 2339-2355, 2023 11 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37682219
8.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Thromb Haemost;
121(3): 351-360, 2021 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33086400
9.
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
Thromb Haemost;
119(7): 1084-1093, 2019 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31064025
10.
Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment.
Nat Commun;
7: 13710, 2016 12 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27966531
11.
Effects and interferences of emicizumab, a humanized bispecific antibody mimicking activated factor VIII cofactor function, on lupus anticoagulant assays.
Int J Lab Hematol;
42(2): e71-e75, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31670901
12.
Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer.
PLoS One;
10(5): e0127063, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25961845
13.
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.
Assay Drug Dev Technol;
11(2): 70-92, 2013 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23046407
14.
High-content, high-throughput analysis of cell cycle perturbations induced by the HSP90 inhibitor XL888.
PLoS One;
6(3): e17692, 2011 Mar 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21408192